News
-
-
PRESS RELEASE
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides, Inc. reports positive pharmacokinetic profile of NV-387 in non-human primate model, showcasing sustained blood concentrations enabling less frequent dosing for its broad-spectrum antiviral agent. The unique polymeric design supports potential against RSV, COVID, and influenza -
-
PRESS RELEASE
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, Inc. elaborates on its groundbreaking host-mimetic, broad-spectrum antiviral technology platform, NV-387, designed to revolutionize viral infection treatment with advanced decoy mechanisms -
-
-
-
PRESS RELEASE
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
NanoViricides, Inc. announces strong antiviral activity of NV-387 against RSV, Influenza A, and Coronaviruses in lethal lung infection models, potentially offering a cure for RSV infection -
-
